Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.

Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM, Long SR

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA27 Aug 2010Cited by 32 (Europe PMC)

PMID20798929DOI10.1007/s00198-010-1297-zPepBankPUB-20798929

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In insurance claims patients receiving teriparatide, average medication possession ratio at 6 months was 0.74.
In plain wordsIn insurance records, patients receiving teriparatide had an average medication possession ratio of 0.74 at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableMedication possession ratio at six months
Study
n = 2,218
Outcome group
Treatment adherence and retention · Whole body
Measurements
Medication possession ratio
0.74 ratio
6 months
Source sentences
Summary
The average MPR at 6 months was 0.74 (N=2,218) and at 12 months, was 0.66 (N=1,303).
1 context sentence(design, population, supporting numbers)
Summary · context
Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2079892901
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In insurance claims patients receiving teriparatide, average medication possession ratio at 12 months was 0.66.
In plain wordsIn insurance records, patients receiving teriparatide had an average medication possession ratio of 0.66 at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableMedication possession ratio at twelve months
Study
n = 1,303
Outcome group
Treatment adherence and retention · Whole body
Measurements
Medication possession ratio
0.66 ratio
12 months
Source sentences
Summary
The average MPR at 6 months was 0.74 (N=2,218) and at 12 months, was 0.66 (N=1,303).
1 context sentence(design, population, supporting numbers)
Summary · context
Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2079892902
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In insurance claims patients receiving teriparatide, 64.6% remained on treatment at 6 months.
In plain wordsIn insurance records, 64.6% of patients remained on teriparatide at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePersistence at six months
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Measurements
Persistence
64.6%
6 months
Source sentences
Summary
At 6 months, 64.6% of patients remained on therapy and at 12 months, 56.7% remained.
1 context sentence(design, population, supporting numbers)
Summary · context
Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2079892903
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In insurance claims patients receiving teriparatide, 56.7% remained on treatment at 12 months.
In plain wordsIn insurance records, 56.7% of patients remained on teriparatide at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePersistence at twelve months
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Measurements
Persistence
56.7%
12 months
Source sentences
Summary
At 6 months, 64.6% of patients remained on therapy and at 12 months, 56.7% remained.
1 context sentence(design, population, supporting numbers)
Summary · context
Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2079892904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.